Insulin glargine is the active ingredient in Lantus. Lantus is one specific brand name for insulin glargine, made by Sanofi. Think of it like the relationship between acetaminophen and Tylenol: glargine is the drug, and Lantus is the product you pick up at the pharmacy. They are not two different medications.
That said, Lantus is no longer the only insulin glargine product on the market. Several alternatives now contain the same active ingredient, and understanding how they relate to each other can affect your cost, your prescription, and whether your pharmacist can make a switch without calling your doctor.
How Insulin Glargine Works
Insulin glargine is a long-acting basal insulin analog that became available in 2000. It was designed to provide a slow, steady release of insulin over the course of a day, mimicking the low-level background insulin your pancreas would normally produce between meals and overnight. It has an onset of about 1.5 to 2 hours after injection and lasts up to 24 hours, which is why most people inject it once daily.
Lantus specifically contains insulin glargine at a concentration of 100 units per milliliter (U-100). It comes in both vials and pre-filled pens (the SoloStar pen). Every other U-100 insulin glargine product on the market is compared against Lantus as the reference.
Other Brands That Contain Glargine
Several insulin glargine products are now available besides Lantus. They all contain the same molecule, but they differ in regulatory status, which has real implications for how your prescription works.
- Semglee (insulin glargine-yfgn): Approved by the FDA in July 2021 as the first interchangeable biosimilar to Lantus. “Interchangeable” is a specific FDA designation that means your pharmacist can substitute Semglee for Lantus without needing a new prescription from your doctor, just as they might swap a generic pill for a brand-name one.
- Basaglar (insulin glargine): Also contains U-100 glargine, but it was approved before the FDA’s current biosimilar comparison process existed. Because Lantus was not formally studied as the reference product during Basaglar’s approval, the two cannot be exchanged at the pharmacy without your prescriber’s authorization. You need a prescription written specifically for Basaglar.
- Rezvoglar (insulin glargine-aglr): Approved in December 2021 as a biosimilar to Lantus, but it does not currently have interchangeable status. Like Basaglar, it requires a prescription written for it by name.
- Toujeo (insulin glargine U-300): This is a three-times more concentrated formulation of insulin glargine at 300 units per milliliter. Despite having the same active molecule, Toujeo is not the same as Lantus. The higher concentration changes how the insulin is absorbed, giving it a longer and flatter activity profile. Toujeo and Lantus are not interchangeable, and switching between them requires dose adjustments under medical supervision.
What “Interchangeable” Actually Means for You
The distinction between a biosimilar and an interchangeable biosimilar matters at the pharmacy counter. If your prescription says “Lantus” and Semglee is available, your pharmacist can fill it with Semglee in most states without contacting your doctor first. This is the same automatic substitution process you’re used to with generic medications.
With Basaglar or Rezvoglar, that automatic swap cannot happen. Your doctor would need to write a new prescription or authorize the change. This doesn’t mean those products are less safe or effective. It simply reflects the regulatory pathway each manufacturer followed during approval.
Switching Between Glargine Products
If you’re moving from Lantus to another U-100 insulin glargine product (or vice versa), the transition is straightforward. Clinical guidance recommends continuing the same dose and the same injection timing. No dose conversion or adjustment period is needed when switching between U-100 glargine products because the active ingredient and concentration are identical.
Switching to or from Toujeo is different. Because the concentration is three times higher, the dose relationship is not one-to-one, and your doctor will need to calculate an appropriate starting dose for the new product.
Cost Differences Between Products
One of the main reasons people search for alternatives to Lantus is price. Biosimilar and interchangeable products typically cost less than the original brand. For Medicare Part D beneficiaries, the Inflation Reduction Act capped out-of-pocket insulin costs at $35 for a 30-day supply starting January 1, 2023, regardless of which insulin glargine product you use. If your supply covers more than 30 days, the cap scales up in 30-day increments (so a 60-day supply caps at $70).
For people with private insurance or no insurance, the savings from choosing Semglee, Basaglar, or Rezvoglar over Lantus can be significant, though exact prices depend on your pharmacy and coverage. Asking your pharmacist to compare costs across the available glargine products is worth doing, especially if your plan’s formulary favors one brand over another.
The Bottom Line on Glargine vs. Lantus
Glargine is the insulin. Lantus is one way to buy it. Every U-100 insulin glargine product contains the same molecule at the same concentration, works for the same duration, and is dosed the same way. The differences come down to brand name, regulatory classification, whether your pharmacist can substitute it automatically, and what you pay out of pocket. If your prescription currently says Lantus and you’re considering a switch for cost reasons, any U-100 glargine product will deliver the same insulin at the same dose.